The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively ...

Novo’s latest investment comes just days after the U.S. FTC greenlit the highly contentious acquisition of Catalent, which ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to support it. Meanwhile, the makers of these drugs have been reporting double-digit ...

Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos ...

Ocaliva recently failed to secure the FDA’s traditional approval for primary biliary cholangitis due to safety concerns.

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

When hiring job candidates to work on cell and gene therapies, companies look for more than just technical skills. Talent ...